Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 2:06 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Hypertriglyceridemia Clear all
Not yet recruiting Not applicable Interventional

Plasma Lipids-dependent Vitamin E Metabolism During Dynamic Hyperlipidemia

NCT07715890
View directory record Official record
Conditions
Lipid Metabolism Disorders
Interventions
High fat liquid shake
Dietary Supplement
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years to 65 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Jul 22, 2026, 2:06 AM EDT
Completed Not applicable Interventional

Effect of Tenofovir Disoproxil Fumarate on Lipid Levels in HIV Infected Adults on Stable Anti-HIV Drug Therapy

NCT00109603
View directory record Official record
Conditions
HIV Infections, Dyslipidemia, Hyperlipidemia, Hypercholesterolemia, Hypertriglyceridemia
Interventions
Tenofovir disoproxil fumarate
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
19
States / cities
Los Angeles, California • San Diego, California • Denver, Colorado + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2012 · Synced Jul 22, 2026, 2:06 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Comparing Tricor, Avandia, or Weight Loss to Lower Cardiovascular Risk Factors in People With High Triglycerides.

NCT00186537
View directory record Official record
Conditions
Insulin Resistance, Hypertriglyceridemia
Interventions
Rosiglitazone, Fenofibrate, Weight Loss
Drug · Behavioral
Lead sponsor
Stanford University
Other
Eligibility
30 Years to 65 Years
Enrollment
47 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2008
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jan 11, 2017 · Synced Jul 22, 2026, 2:06 AM EDT
Terminated Not applicable Interventional Results available

Intravenous Fat Emulsions and Premature Infants

NCT01096446
View directory record Official record
Conditions
Hypertriglyceridemia, Hyperglycemia
Interventions
Intravenous Fat Emulsions
Drug
Lead sponsor
OSF Healthcare System
Other
Eligibility
1 Day to 2 Days
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Peoria, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 19, 2014 · Synced Jul 22, 2026, 2:06 AM EDT
Completed Phase 1 Interventional

Safety Study of LLF580 in Obese Volunteers

NCT03466203
View directory record Official record
Conditions
Obesity
Interventions
LLF580, Placebo
Biological · Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
7
States / cities
Jacksonville, Florida • Miami, Florida • Overland Park, Kansas + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 11, 2021 · Synced Jul 22, 2026, 2:06 AM EDT
Suspended Phase 2 Interventional

Evaluate the Safety and Efficacy of Saroglitazar Mg in Patients With Fasting Triglyceride ≥500 mg/dL and ≤1500 mg/dL

NCT03097107
View directory record Official record
Conditions
Dyslipidemias
Interventions
Saroglitazar Magnesium 1 mg, Saroglitazar Magnesium 2 mg, Saroglitazar Magnesium 4 mg, Placebo
Drug
Lead sponsor
Zydus Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
33
States / cities
Huntsville, Alabama • Encinitas, California • San Diego, California + 29 more
Source: ClinicalTrials.gov public record
Updated Feb 7, 2023 · Synced Jul 22, 2026, 2:06 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

The Effect of Multiple Doses of Epanova® on the Multiple-Dose Pharmacokinetics of Simvastatin in Healthy Normal Subjects

NCT01486433
View directory record Official record
Conditions
Hypertriglyceridemia
Interventions
Simvastatin, acetylsalicylic acid (ASA), omefas
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Apr 29, 2015 · Synced Jul 22, 2026, 2:06 AM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

Study of Trilipix Effects on Lipids and Arteries

NCT01025492
View directory record Official record
Conditions
Dyslipidemia
Interventions
Trilipix, placebo
Drug
Lead sponsor
University of Utah
Other
Eligibility
30 Years to 75 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Aug 31, 2016 · Synced Jul 22, 2026, 2:06 AM EDT
Recruiting Phase 2 Interventional

A Mechanistic Study of MAR001 in Adults With Elevated Triglycerides and Remnant Cholesterol

NCT07199309
View directory record Official record
Conditions
Hypertriglyceridemia
Interventions
MAR001, Placebo
Drug
Lead sponsor
Marea Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Nov 5, 2025 · Synced Jul 22, 2026, 2:06 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

PK Study Comparing Metformin Eicosapentaenoate to a Combined Dose of Metformin Hydrochloride and Ethyl Ester EPA

NCT02113163
View directory record Official record
Conditions
Diabetes Mellitus, Non-Insulin-Dependent, Hypertriglyceridemia
Interventions
Metformin Eicosapentaenoate, Metformin HCl and Vascepa
Drug
Lead sponsor
Thetis Pharmaceuticals LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated May 1, 2022 · Synced Jul 22, 2026, 2:06 AM EDT
Completed Phase 3 Interventional

A Phase 3 STudy of CaPRe In LOwering Very hiGh TriglYcerides (TRILOGY 1)

NCT03398005
View directory record Official record
Conditions
Hypertriglyceridemia
Interventions
CaPre, Placebo
Drug
Lead sponsor
Grace Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
256 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
69
States / cities
Birmingham, Alabama • Tucson, Arizona • Conway, Arkansas + 57 more
Source: ClinicalTrials.gov public record
Updated Jan 17, 2020 · Synced Jul 22, 2026, 2:06 AM EDT
Completed Not applicable Interventional

Genetic Effect on Omega 3 Fatty Acids for the Treatment of Fatty Liver Disease

NCT01556113
View directory record Official record
Conditions
Non Alcoholic Fatty Liver Disease, Steatohepatitis, Hypertriglyceridemia, Alanine Aminotransferase, Plasma Level of, Quantitative Trait Locus 1
Interventions
Omega diet
Other
Lead sponsor
Yale University
Other
Eligibility
10 Years to 19 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 27, 2017 · Synced Jul 22, 2026, 2:06 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effect of Fish Oil on Plasma Triglycerides in Adults

NCT00804427
View directory record Official record
Conditions
Hypertriglyceridemia
Interventions
Fish oil (90% triglycerides), Fish oil (60% triglycerides), Fish oil (ethyl esters), Soy oil
Dietary Supplement
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Feb 21, 2023 · Synced Jul 22, 2026, 2:06 AM EDT
Not listed Phase 3 Interventional

Efficacy Study to Treat Subjects With Severe Hypertriglyceridemia

NCT01229566
View directory record Official record
Conditions
Severe Hypertriglyceridemia
Interventions
AKR-963
Drug
Lead sponsor
Trygg Pharma, Inc.
Industry
Eligibility
18 Years to 79 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 23, 2011 · Synced Jul 22, 2026, 2:06 AM EDT
Completed Phase 2 Interventional Results available

Efficacy, Safety and Tolerability of ISIS 304801 in People With Partial Lipodystrophy With an Open-Label Extension

NCT02639286
View directory record Official record
Conditions
Lipodystrophy
Interventions
ISIS 304801, Placebo
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 19, 2020 · Synced Jul 22, 2026, 2:06 AM EDT
Completed Phase 2 Interventional Results available

Effects of Acipimox on Mitochondrial Function in Obesity

NCT01488409
View directory record Official record
Conditions
Abdominal Obesity, Insulin Resistance, Hypertriglyceridemia
Interventions
Acipimox, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 55 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 29, 2016 · Synced Jul 22, 2026, 2:06 AM EDT
Recruiting Phase 1 Interventional

A Safety and Tolerability Trial Evaluating CTX310 in Participants With Refractory Dyslipidemias

NCT07491172
View directory record Official record
Conditions
Cardiovascular, Metabolic Disease, Dyslipidemias, Lipid Disorder, Hypertriglyceridemia, Heterozygous Familial Hypercholesterolemia (HeFH), Homozygous Familial Hypercholesterolemia (HoFH), Severe Hypertriglyceridemia (sHTG), Mixed Hyperlipemia, Hypercholesterolaemia
Interventions
CTX310
Drug
Lead sponsor
CRISPR Therapeutics AG
Industry
Eligibility
18 Years to 75 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
10
States / cities
Hialeah, Florida • High Point, Florida • Jacksonville, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2026 · Synced Jul 22, 2026, 2:06 AM EDT
Terminated Phase 2 Interventional Results available

Trial of Lovaza in Adolescents With Mild to Moderately Elevated Triglycerides

NCT00672633
View directory record Official record
Conditions
Hypertriglyceridemia
Interventions
Lovaza, Placebo
Drug
Lead sponsor
Boston Children's Hospital
Other
Eligibility
10 Years to 19 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 28, 2013 · Synced Jul 22, 2026, 2:06 AM EDT
Active, not recruiting Phase 2 Interventional

MN-001 in Non-alcoholic Fatty Liver Disease, Type 2 Diabetes Mellitus, and Hypertriglyceridemia

NCT05464784
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Hypertriglyceridemia, Non-Alcoholic Fatty Liver Disease
Interventions
MN-001, MN-001 placebo
Drug
Lead sponsor
MediciNova
Industry
Eligibility
21 Years to 75 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
2
States / cities
Las Vegas, Nevada • Edinburg, Texas
Source: ClinicalTrials.gov public record
Updated Feb 4, 2026 · Synced Jul 22, 2026, 2:06 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Assess the Safety and Tolerability of Single Doses of REGN1500

NCT01749878
View directory record Official record
Conditions
Hypertriglyceridemia
Interventions
REGN1500, placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
99 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2016
U.S. locations
2
States / cities
Philadelphia, Pennsylvania • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated May 11, 2016 · Synced Jul 22, 2026, 2:06 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy Study Comparing ABT-143 to Simvastatin in Subjects With Elevated Levels of Low Density Lipoprotein Cholesterol ("Bad Cholesterol") and Triglycerides

NCT00812955
View directory record Official record
Conditions
Dyslipidemia, Hypercholesterolemia, Hypertriglyceridemia
Interventions
ABT-143, simvastatin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
474 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
129
States / cities
Birmingham, Alabama • Columbiana, Alabama • Huntsville, Alabama + 110 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2012 · Synced Jul 22, 2026, 2:06 AM EDT
Completed Phase 3 Interventional Results available

Changes in Lipids and Safety of Raltegravir in HIV+ Patients With Hyperlipidemia While on Current Standard Therapy

NCT00887653
View directory record Official record
Conditions
HIV, Hyperlipidemia, Hypertriglyceridemia, HIV Infections
Interventions
raltegravir
Drug
Lead sponsor
The Miriam Hospital
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
2
States / cities
Boston, Massachusetts • Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Oct 9, 2014 · Synced Jul 22, 2026, 2:06 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effects of Amino Acids on Regional Lipid Metabolism

NCT01150188
View directory record Official record
Conditions
Hypertriglyceridemia
Interventions
Amino acids, Placebo
Dietary Supplement
Lead sponsor
University of Arkansas
Other
Eligibility
50 Years to 75 Years
Enrollment
125 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2016
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Oct 26, 2016 · Synced Jul 22, 2026, 2:06 AM EDT
Completed Phase 2 Interventional Results available

Study to Explore the Efficacy and Safety of BIO89-100 (Pegozafermin) in Participants With Severe Hypertriglyceridemia

NCT04541186
View directory record Official record
Conditions
Severe Hypertriglyceridemia
Interventions
Pegozafermin, Placebo
Drug
Lead sponsor
89bio, Inc.
Industry
Eligibility
21 Years to 75 Years
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
32
States / cities
La Mesa, California • San Francisco, California • Clearwater, Florida + 26 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2024 · Synced Jul 22, 2026, 2:06 AM EDT